Protocol Information

If you are interested in learning more about this study, please call or email the contact person below

Title Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients with Chronic Heart Failure with Reduced Ejection Fraction. D1699C00001
Description The purpose of this study is to see if dapagliflozin is effective in heart failure by reducing the number of hospitalizations due to heart failure, or worsening of heart failure events, and in the long run to improve the survival for patients with heart failure. The study will include patients with type 2 diabetes as well as patients who do not have diabetes. As this is a research study, there is no guarantee that, should you be treated with dapagliflozin, your heart failure will improve.

Participants may be expected to complete 8-14 study visits.

Study visits will be in downtown Buffalo or Williamsville

If you're interested, please contact the study contact listed below.
Principal Investigator CIMATO, THOMAS
Age Group Adult
Drugs Involved
Status Open
Key Eligibility Age 18 or older
Heart failure with reduced ejection fraction
do NOT have Type 1 Diabetes
Disease Group Diabetes; Heart Diseases
Treatment dapagliflozin
+1 716-859-4641